公开(公告)号：US20190022062A1

公开(公告)日：2019-01-24

申请号：US16114076

申请日：2018-08-27

Applicant: Oncternal Therapeutics, Inc.

Inventor： Brian Lannutti ,  Katayoun Jessen ,  James Bradley Breitmeyer

IPC: A61K31/404 ,  A61K31/496 ,  A61K39/395 ,  C07K16/28 ,  A61K31/551

Abstract: Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.

公开(公告)号：US10159660B2

公开(公告)日：2018-12-25

申请号：US15660566

申请日：2017-07-26

Applicant: Oncternal Therapeutics, Inc.

Inventor： Brian Lannutti ,  Katayoun Jessen ,  James Bradley Breitmeyer

IPC: A61K31/40 ,  A61K31/497 ,  A61K31/404 ,  A61K31/496 ,  A61K31/551 ,  C07K16/28 ,  A61K39/395

Abstract: Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.

公开(公告)号：US20170066720A1

公开(公告)日：2017-03-09

申请号：US15357876

申请日：2016-11-21

Applicant: Oncternal Therapeutics, Inc.

Inventor： Jean-Michel Vernier

IPC: C07D209/38 ,  C07D401/06 ,  C07D403/10

CPC classification number: A61K31/404 ,  A61K31/4155 ,  A61K31/4439 ,  A61K31/5377 ,  C07D209/34 ,  C07D209/38 ,  C07D401/06 ,  C07D401/10 ,  C07D403/10

Abstract: Indolinone derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indolinone derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.

公开(公告)号：US12187720B2

公开(公告)日：2025-01-07

申请号：US17370201

申请日：2021-07-08

Applicant: ONCTERNAL THERAPEUTICS, INC. ,  UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

Inventor： Wei Li ,  Duane D Miller ,  Kinsie E. Arnst ,  Dong-Jin Hwang

IPC: C07D417/14 ,  A61P35/00 ,  C07C49/786 ,  C07D211/14 ,  C07D213/76 ,  C07D217/04 ,  C07D233/64 ,  C07D277/24 ,  C07D405/06 ,  C07D417/04 ,  C07D417/12

Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.

公开(公告)号：US20230070988A1

公开(公告)日：2023-03-09

申请号：US17759681

申请日：2021-01-29

Applicant: ONCTERNAL THERAPEUTICS, INC.

Inventor： Gunnar KAUFMANN

IPC: A61K31/506 ,  A61K31/501 ,  A61K31/52 ,  A61K31/519 ,  A61K39/395 ,  A61P35/00

Abstract: Described herein is a method of treating a cancer in an individual comprising administering a tyrosine kinase-like orphan receptor 1 (ROR1) antagonist and an epidermal growth factor receptor (EGFR) inhibitor. In some embodiments, the ROR1 antagonist is cirmtuzumab. In some embodiments, the EGFR inhibitor is osimertinib. In some embodiments, the cancer is a lung cancer such as a non-small cell lung cancer.

公开(公告)号：US09895352B2

公开(公告)日：2018-02-20

申请号：US15357933

申请日：2016-11-21

Applicant: Oncternal Therapeutics, Inc.

Inventor： Jean-Michel Vernier

IPC: A61K31/404 ,  A61K31/5377 ,  A61K31/4439 ,  A61K31/4155 ,  C07D209/38 ,  C07D401/06 ,  C07D401/10 ,  C07D403/10 ,  C07D209/34

CPC classification number: A61K31/404 ,  A61K31/4155 ,  A61K31/4439 ,  A61K31/5377 ,  C07D209/34 ,  C07D209/38 ,  C07D401/06 ,  C07D401/10 ,  C07D403/10

Abstract: Indolinone derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indolinone derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.

公开(公告)号：US20180028495A1

公开(公告)日：2018-02-01

申请号：US15660566

申请日：2017-07-26

Applicant: Oncternal Therapeutics, Inc.

Inventor： Brian Lannutti ,  Katayoun Jessen ,  James Bradley Breitmeyer

IPC: A61K31/404 ,  C07K16/28 ,  A61K31/496 ,  A61K31/551

CPC classification number: A61K31/404 ,  A61K31/496 ,  A61K31/551 ,  A61K39/39558 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/73 ,  A61K2300/00

Abstract: Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.

公开(公告)号：US12128026B2

公开(公告)日：2024-10-29

申请号：US17694183

申请日：2022-03-14

Applicant: University of Tennessee Research Foundation ,  Oncternal Therapeutics, Inc.

Inventor： Ramesh Narayanan ,  Duane D. Miller ,  Thamarai Ponnusamy ,  Dong-Jin Hwang ,  Yali He ,  Jayaprakash Pagadala ,  Christopher C. Coss ,  James T. Dalton ,  Charles B. Duke

IPC: A61K31/404 ,  A61K31/403 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/437 ,  A61K31/47 ,  A61K31/472 ,  A61P35/00

CPC classification number: A61K31/404 ,  A61K31/403 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/437 ,  A61K31/47 ,  A61K31/472 ,  A61P35/00

Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

公开(公告)号：US11591290B2

公开(公告)日：2023-02-28

申请号：US16776395

申请日：2020-01-29

Applicant: ONCTERNAL THERAPEUTICS, INC ,  University of Tennessee Research Foundation

Inventor： Ramesh Narayanan ,  Duane D. Miller ,  Thamarai Ponnusamy ,  Dong-Jin Hwang ,  Charles B. Duke ,  Christopher C. Coss ,  Amanda Jones ,  James T. Dalton

IPC: C07C237/00 ,  C07C237/20 ,  A61P35/00 ,  A61P25/00 ,  A61P5/28

Abstract: This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other 5 hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

公开(公告)号：US20220024912A1

公开(公告)日：2022-01-27

申请号：US17370201

申请日：2021-07-08

Applicant: ONCTERNAL THERAPEUTICS, INC. ,  UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

Inventor： Wei LI ,  Min XIAO ,  James DALTON ,  Sunjoo AHN ,  Duane D. MILLER ,  Jin WANG

IPC: C07D417/14 ,  C07D277/24 ,  C07D213/76 ,  C07D405/06 ,  C07D417/12 ,  A61P35/00 ,  C07D417/04 ,  C07D233/64 ,  C07C49/786 ,  C07D217/04 ,  C07D211/14

Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.